
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$176.6b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$103.50
7D
-3.7%
1Y
-14.8%
Bora Pharmaceuticals
Market Cap: NT$52.9b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$394.00
7D
-7.5%
1Y
-43.9%
Lotus Pharmaceutical
Market Cap: NT$52.0b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$188.50
7D
-7.6%
1Y
-15.1%
Oneness Biotech
Market Cap: NT$24.1b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$48.65
7D
-10.2%
1Y
-24.7%
TaiMed Biologics
Market Cap: NT$18.0b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$59.80
7D
-14.0%
1Y
-31.5%
Medigen Vaccine Biologics
Market Cap: NT$15.7b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$46.10
7D
-2.7%
1Y
10.8%
Foresee Pharmaceuticals
Market Cap: NT$12.9b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$80.10
7D
-3.6%
1Y
13.8%